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Lacking prognostic signficance ofP1-microglobulin, MHC class I and
class II antigen expression in breast carcinomas
H.-O. Wintzer*, M. Benzing & S. von Kleist
Institute ofImmunobiology, Medical Faculty, University ofFreiburg, Stefan-Meier-Str. 8, D-7800 Freiburg, Federal Republic of
Germany.
Summary To evaluate the impact of MHC antigen expression on the survival of patients with cancer, 77
human breast carcinomas were investigated for the expression of P2-microglobulin (02m), HLA-A,B,C and
HLA-DR. Thirty-one benign breast tumours were stained for comparison. The results for the carcinomas were
related to the survival data of the cancer patients. The expression of P2m, HLA-A,B,C and HLA-DR was
significantly lower in malignant tumours compared to the benign lesions. Whereas all benign tumours were
positive for P2m and HLA-A,B,C and 28/31 positive for HLA-DR the following positivity rates were found in
carcinomas: 74/77 for P2m, 57/77 for HLA-A,B,C and 10/77 for HLA-DR. The follow-up (median 45 months)
of 66 cancer patients for overall survival and of 65 patients for disease-free survival revealed no influence of
P2m, HLA-A,B,C or HLA-DR expression on the prognosis of this cancer. In conclusion, experimental data
indicating the importance of MHC antigens in anti-tumour responses are not confirmed by the analysis of
cancer patient survival data.
The classical class I genes HLA-A, HLA-B and HLA-C
encode for an a-chain which associates with P2-microglobulin
(02m) to be expressed on the cell membrane. Class II genes
are subdivided into the subregions HLA-DR, -DQ and -DP
which encode for cx/p heterodimeric membrane antigens
(Guillemot et al., 1988). MHC class I antigens are expressed
on the majority of normal nucleated cells (Daar et al., 1984a)
whereas the distribution ofclass II antigens in normal tissues
is more restricted (Daar et al., 1984b). The physiological role
of MHC antigens lies in their restrictive function for T-cell
immune recognition and immune response. CD4 positive T-
cell subsets recognise antigen in the context of MHC class II
molecules, CD8 positive cells in association with MHC class
I antigens (Hedrick, 1988).
Based on animal tumour models there is ample evidence
that the loss of MHC class I antigen expression allows
tumour growth and metastasis formation by escape from
T-cell mediated surveillance (Doherty et al., 1984;
Hammerling et al., 1987; Tanaka et al., 1988). The involve-
ment of MHC class I antigens in the in vitro lysis of tumour
cells by specific cytotoxic T-lymphocytes is well documented
(Anichini et al., 1985; V'anky, 1986; Roberts et al., 1987;
V'anky et al., 1987; Itoh et al., 1988; Darrow et al., 1989;
Knuth et al., 1989).
Less is known about the immunological implications of
MHC class II expression on tumour cells. In vitro assays,
using autologous fresh tumour cells to stimulate peripheral
blood lymphocytes, indicated that the presence of HLA-DR
antigens was not related to the proliferative response of the
lymphocytes for a variety of malignomas (Vanky et al., 1985;
Vanky, 1986) and for ovarian carcinomas (Di Bello et al.,
1988). In primary malignant melanomas (not included in the
series of Vatnky) the induction of proliferation correlated
with the expression of HLA-DR on fresh tumour cells and
could be blocked by anti-HLA-DR antibodies. In contrast,
metastatic melanomas induced proliferative responses in a
minority of cases only (Fossati et al., 1984; Parmiani et al.,
1985). Using melanoma cell lines established from early and
advanced disease, Guerry et al. (1984) reported on the HLA-
DR dependent stimulation of lymphocytes by early stage
melanomas whereas advanced melanomas failed to induce
proliferation.
MHC antigens have repeatedly been demonstrated in
human breast tumours (Fleming et al., 1981; Natali et al.,
1981, 1983, 1984, 1986; Weiss et al., 1981; Bhan & Des-
Marais, 1983; Rowe & Beverley, 1984; Sawtell et al., 1984;
Sidky & Walker, 1984; Whitwell et al., 1984; Gottlinger et
al., 1985; Hurlimann & Saraga, 1985; Perez et al., 1986; Zuk
& Walker, 1987; Muller & Stutte, 1988). Sawtell et al. (1984)
found a correlation between the histological, not cytological,
tumour differentiation and the expression of P2m and MHC
class I antigens. Sidky & Walker (1984) observed that histo-
logically poorly differentiated carcinomas stained less for
P2m- Zuk & Walker (1987) demonstrated a correlation
between tumour grading and the expression of P2m and
HLA-A,B,C. Regarding the prognostic value of tumour
grading for breast cancer patients (Bloom & Richardson,
1957; Freedman et al., 1979; Haybittle et al., 1982; Reiner et
al., 1985; Russo et al., 1987; Chevallier et al., 1988), the
expression of MHC class I antigens on survival can be
expected to influence survival as well. However, to our
knowledge, no report on the relation of MHC antigen ex-
pression in breast cancers and the survival of tumour patients
has yet been published. Therefore, we studied the expression
of MHC antigens including P2m in breast carcinomas in
comparison to benign breast lesions and related our staining
results to the survival data of the cancer patients.
Materials and methods
Patients
Between 1982 and 1985 representative samples of 31 benign
and 77 malignant breast lesions were collected at the time of
surgery at the Department of Surgery of the Evangelisches
Diakoniekrankenhaus, Freiburg. The benign lesions consisted
of 23 mastopathies, 4 fibroadenomas, 2 cases of mastitis, 1
lobular hyperplasia and 1 gynaecomastia. The carcinomas
included 66 invasive ductal carcinomas, 6 of which had a
predominant intraductal component, 2 intraductal, 6 invasive
lobular, 2 mucinous carcinomas and one medullary car-
cinoma. The diagnoses of all specimens were confirmed histo-
pathologically. The age of the tumour patients ranged from
28 to 83 years (mean 60.9 years) compared with a range of
14 to 72 years (mean 44.6 years) for patients with benign
lesions. The carcinomas were staged according to the UICC
pTNM classification (UICC, 1987; Table I). Table II demon-
strates the carcinomas grouped by the number of axillary
lymph node metastases and hormone receptor status. Oestro-
gen receptor (ER) and progesterone receptor (PR) levels were
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Table I Carcinomas listed according to the T-, N- and M-stages of
the pTNM-classification
Ti T2 T3 T4 NO Ni N2 MO Ml
n 24 37 11 5 35 33 9 70 4*
In 3 cases no information on the M-status was available, which
were T2 NO MX, T2 NI MX and T3 N2 MX.
Table II Carcinomas listed according to the number of axillary
lymph node metastases and hormone receptor status
N =Oa N = 1-3b N>3c HR+d HR-'
n 35 30 12 54 16f
aCarcinomas without axillary lymph node metastases. Carcinomas
with up to 3 axillary lymph node metastases. cCarcinomas with more
than 3 axillary lymph node metastases. dER and/or PR>20 fmolmg-'
cytosol protein. "ER and PR<20fmolmg-' cytosol protein. 'For
two carcinomas no receptor concentrations were available and for
five carcinomas only a negative ER value was obtained.
expressed as fmol mg-' cytosol protein. ER and PR values of
smaller than 20 fmol mg- I were considered negative. Car-
cinomas were classified as hormone receptor positive (at least
one receptor concentration positive) or hormone receptor
negative (ER-/PR-).
Tissue preparation
The fresh tissue samples were snap-frozen in liquid nitrogen
and stored at - 70°C until use. Serial cryostat sections were
cut at 5 ym, air-dried at least for 2 h and fixed in acetone for
10 min at room temperature (RT). The sections were stored
at - 20°C until staining, however, for 4 weeks at maximum.
Monoclonal antibodies and antisera
The following MoAbs were used: L 368 against P2-
microglobulin (Lampson et al., 1983), obtained from Becton-
Dickinson, W 6/32 against a monomorphic determinant of
HLA-A,B,C antigens (Barnstable et al., 1978), kindly pro-
vided by Dr. F. Momburg (DKFZ, Heidelberg, FRG) and
L 243 against HLA-DR (Lampson & Levy, 1980), purchased
from Becton-Dickinson. Biotinylated horse anti-mouse IgG
and avidin-biotinylated peroxidase complex (ABC) were
obtained from Vector.
Immunoperoxidase staining
The sections were thawed, fixed in acetone for 10 min at RT
and rehydrated in PBS (0.04 M, pH 7.4). They were incubated
with the first antibody for 30 min at 37°C, then with the
second biotinylated horse anti-mouse IgG for 30 min at RT
and finally with the ABC for 45 min at RT. After each
incubation step the sections were washed three times in PBS.
Peroxidase was visualised with DAB in 0.06% hydrogen
peroxide. The colour of the DAB precipitation product was
intensified by 0.5% copper sulphate in physiological saline.
The sections were counterstained with hematoxylin. Negative
controls were carried out by replacing the primary antibody
by PBS. Stromal cells which were ubiquitously present served
as intrinsic positive controls for the immunoreactivity of the
MoAbs. Blocking of endogenous peroxidase activity was not
necessary since endogenous peroxidase activity, if present at
all, did not interfere with the interpretation of the specific
staining results.
Interpretation ofimmunohistological results
In order to evaluate the antigen expression in a semiquanti-
tative manner, the following score was applied:
No staining (-); slight staining irrespective of the number
of positive tumour (or epithelial) cells, or moderate to
strong staining of less than one third of the cells (+);
moderate staining of more than one third of the cells, or
strong staining of one to two thirds of the cells (+ +);
strong staining of more than two thirds of the cells
(+ + +). If residual non-neoplastic epithelial structures
were found in the carcinoma sections they were evaluated
separately.
Follow-up
Follow-up data of patients with malignancies were collected
by means of inquiries of the treating physicians and by
review of the medical records of the Surgical Ambulance,
Evangelisches Diakoniekrankenhaus, and the Department of
Radiotherapy, University of Freiburg. Patients with distant
metastases at the time of diagnosis or whose M-status was
unknown were excluded from the follow-up (n = 6). Inform-
ation was retained about the vital status, recurrence ofcancer
and the cause of death. The date of histopathological diag-
nosis of the carcinoma was regarded as the start of follow-
up. Data (n = 54) include the date of the last observation of
patients alive or the date of death from patients who died
from causes other than carcinoma, or from those whose
cause of death was unknown. For five patients no inform-
ation about their postsurgical status could be obtained; they
were not considered for the analysis of overall survival. For
the analysis of disease-free survival 48 cases provided data.
Six patients for whom no information on the relapse was
available were excluded. The follow-up time ranged from 26
to 81 months (median 45 months).
Statistical methods
The statistical analysis of the data was performed by the
Department of Medical Biometrics and Medical Informatics,
University of Freiburg. To check for correlations between the
expression of MHC antigens and the histological type of
lesions and to test the difference in staining results between
benign and malignant tumours the x2 test was used, while the
Sign test was employed to correlate antigen expression in
tumor cells with the expression in residual non-neoplastic
epithelium. Survival curves were estimated according to
Kaplan-Meier and the log-rank, Wilcoxon and the likelihood
ratio test were applied as tests of significance. The computing
was done by the SAS procedure LIFETEST.
The identification of independent prognostic effects of
MHC antigen expression was assessed by the Cox multi-
variate regression analysis. The characteristics which were
included were the pT-stage grouped in two categories, Ti -2
and T3-4; two groups formed according to the number of
axillary lymph node metastases; and those without, or with
up to 3, and those with more than 3 positive nodes. Car-
cinomas were classified as hormone receptor positive or
negative. The age of patients was included as a continuous
variable. If any of the above information was not available,
patients were excluded, resulting in 63 patients studied for
overall and 62 patients for disease-free survival. The Cox
regression analysis was computed with BMDP2L, from
BMDP Statistical Software, Los Angeles, California. The
computing comprised the elimination of single covariates
tested against the complete model as well as stepwise-up and
stepwise-down regressions. To test for significance the Wald,
likelihood ratio, score and x2 test were applied.
Results
Immunohistology
The staining results of the benign breast lesions are sum-
marised in Table III. No benign tissue was completely
negative for P2m or HLA-A,B,C antigens. On comparing
anti-P2m MoAb with anti-HLA-A,B,C MoAb staining, equal
or weaker scores were found for the latter. The antigens were
located on the cell membranes as well as in the cytoplasm.
Heterogeneity of antigen expression (Figure 1) was observedMHC ANTIGENS IN BREAST TUMOURS AND PROGNOSIS 291
Table III Staining results of benign breast lesions
Staining score
MoAb - + + + + + + Total
L 368 0 2 14 15 31
W 6/32 0 16 15 0 31
L243 3 19 9 0 31
Figure 1 Mastopathy showing heterogeneous expression of
HLA-DR. Hematoxylin counterstain. Scale bar: 50 lm.
for P2m, HLA-A,B,C and HLA-DR. Three tissues (all masto-
pathies) were negative for HLA-DR. Its expression in the
remaining samples generally was lower compared to the ex-
pression of P2m or HLA-A,B,C. In just one case of hyper-
plasia and in the gynaecomastia, higher scores were obtained
with MoAb L 243.
No correlation was found between the histological type of
the benign lesions and the immunohistological demonstration
Of P2m or MHC antigens (X2 test). Table IV displays the
results obtained with malignant tumours, which showed
membrane as well as cytoplasmic staining patterns (Figures 2
and 3). In contrast to benign lesions, the breast carcinomas
were characterised by a reduction in the expression of P2m
and MHC antigens. This difference proved to be statistically
significant (X2 test, L 368; P <0.05; W 6/32; P <0.01; L 243;
P <0.001). Three of 77 malignancies were completely
negative for P2m and 20/77 for HLA-A,B,C antigens. In
comparison to MoAb L 368, MoAb W 6/32 resulted in lower
staining scores in carcinomas as well.
By far the majority of malignancies (67/77) proved to be
HLA-DR-negative. When carcinomas were positive, the
HLA-DR expression was always lower than the expression of
HLA-A,B,C or P2m, and the staining was situated in tumour
areas which were also HLA-A,B,C-positive. No tumour
showed staining of all carcinoma cells with MoAb L 243. No
correlation was found between the histological type, the ex-
pression pTNM stage, the ER or PR level of the carcinomas
and the demonstration of MHC antigens. In 13/77 carcinoma
samples residual non-neoplastic gland epithelium could be
detected (Figure 4). Its antigen expression was evaluated
separately and compared to that in the tumour cells (Table
V). For MoAbs L 368 and W 6/32 no significant difference in
staining between cancer cells and epithelium was found,
while, the lower expression of HLA-DR in carcinoma cells
was significant.
Survival analysis - Kaplan-Meier estimates
Overall survival Significant differences between survival
curves were obtained for the variables: nodal status
(P <0.01) and hormone receptor status (P <0.01). Patients
with not more than 3 positive lymph nodes and hormone
receptor positive tumours were characterised by a better
prognosis regarding overall survival. According to the Pm
Table IV Staining results of malignant breast lesions
Staining score
MoAb - + + + + + + Total
L 368 3 26 32 16 77
W 6/32 20 41 13 3 77
L243 67 8 2 0 77
Figure 2 Predominantly membranous staining of an invasive
ductal carcinoma by anti-P2m. Hematoxylin counterstain. Scale
bar: 50jtm.
Figure 3 Cytoplasmic HLA-A,B,C expression in an invasive
lobular carcinoma. Hematoxylin counterstain. Scale bar: 50#&m.
Figure 4 Residual non-neoplastic epithelium strongly stained for
HLA-DR whereas adjacent carcinoma cells are negative.
Hematoxylin counterstain. Scale bar: 50 um.292 H.-O. WINTZER et al.
expression the patients were classified into three groups: -
and + (n = 25); + + (n = 26); + + + (n=15). For HLA-
A,B,C the following classes were formed: - (n = 16); +
(n = 36); + + and + + + (n = 14). HLA-DR expression
resulted in two classes: - (n = 57); + and + + (n = 9).
None of these 3 parameters produced significant differences
in the survival curves (Figure 5).
Disease-free survival In contrast to overall survival, the pT-
stage influenced disease-free survival in our cohort
(P <0.01). Axillary lymph node status (P <0.01) and hor-
mone receptor status (P <0.05) also resulted in significantly
different disease-free survival curves. Patients with smaller
tumours, less than 4 axillary lymph node metastases or hor-
mone receptor positive carcinomas, showed a more
Table V Staining results of carcinoma cells compared to those of
residual non-neoplastic epithelium found in the same section
MoAb C<Ea C=Eb C>EC Total pd
L 368 6 6 1 13 0.1250
W 6/32 5 7 1 13 0.2188
L 243 10 3 0 13 0.0020
aCarcinoma cells stained weaker than residual epithelium.
bCarcinoma cells stained like residual epithelium. cCarcinoma cells
stained stronger than residual epithelium. dLevel of significance
according to the sign test.
favourable prognosis. No effect of P2m, HLA-A,B,C or
HLA-DR expression on disease-free survival was observed
using the same classification of patients as for overall sur-
vival (Figure 6).
Cox analysis To exclude the theoretical possibility that the
effect of antigen expression in the Kaplan-Meier estimates
was covered by other factors Cox multivariate regression
analyses were carried out. The Cox analysis of overall sur-
vival data resulted in only two variables being of prognsotic
importance irrespective of the computing method, i.e., the
number of axillary lymph nodes (P <0.01) and the hormone
receptor status (P <0.01). For the disease-free survival data,
no effect of MHC expression was seen. Again, the number of
positive axillary lymph nodes (P<0.05) and the hormone
receptor status (P <0.05) were of importance, together with
the pT-stage, only in the stepwise-up regression (P<0.01).
Discussion
The immunohistological examination of 31 benign and 77
malignant human breast tumours revealed a lower expression
of HLA-A,B,C and -DR antigens and P2m in the malignant
tumours. In 13 carcinoma samples which included residual
gland epithelium, the HLA-DR expression in the tumour
cells was reduced compared to their normal counterparts. ,_.....,.,.u...-----
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Figure 5 Kaplan-Meier estimates for overall survival. The
classification of the carcinoma patients according to P2m (upper
graph), HLA-A,B,C (middle graph) and HLA-DR (lower graph)
expression did not result in different clinical courses. The solid
lines represent carcinomas which were scored as '-' or '+' for
P2M or '-' for HLA-A,B,C and HLA-DR, respectively. The
dashed lines represent carcinomas scored as '+ +' for P2m, '+'
for HLA-A,B,C and '+' or '+ +' for HLA-DR. The dotted lines
represent carcinomas scored as '+ + +' for P2m and '+ +' or
'+ + +' for HLA-A,B,C. The P-values obtained by the logrank,
Wilcoxon and likelihood ratio tests were 0.44, 0.32 and 0.53,
respectively for P2m; 0.38, 0.35 and 0.36, respectively for HLA-
A,B,C; 0.48, 0.60 and 0.54, respectively for HLA-DR.
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classification of the carcinoma patients according to P2m (upper
graph), HLA-A,B,C (middle graph) and HLA-DR (lower graph)
expression did not result in different clinical courses. The solid
lines represent carcinomas which were scored as -' or '+' for
P2M or '-' for HLA-A,B,C and HLA-DR, respectively. The
dashed lines represent carcinomas scored as '+ +' for P2m, '+'
for HLA-A,B,C and '+' or '+ +' for HLA-DR. The dotted lines
represent carcinomas scored as '+ + +' for P2m and '+ +' or
'+ + +' for HLA-A,B,C. The P-values obtained by the logrank,
Wilcoxon and likelihood ratio tests were 0.33, 0.28 and 0.53,
respectively for P2m; 0.38, 0.27 and 0.40, respectively for HLA-
A,B,C; 0.68, 0.57 and 0.83, respectively for HLA-DR.
_ 1.0 (U
0.8
X) 0.6
CD
* 0.4
10 E 0.2
m
.
(U
U)
a)
:3
I 1. ,11. .
0-0 1. .I V.vI
,I W,....
1i
1
11
1MHC ANTIGENS IN BREAST TUMOURS AND PROGNOSIS 293
The high expression of HLA-A,B,C and P2m and a lower
expression of HLA-DR in benign lesions are in concordance
with the results of other studies (Weiss et al., 1981; Bhan &
DesMarais, 1983; Rowe & Beverley, 1984; Sidky & Walker,
1984; Whitwell et al., 1984; Zuk & Walker, 1987) and corre-
spond to the demonstration of these antigens in normal
human breast tissue (Daar et al., 1984a, 1984b; Natali et al.,
1983). Likewise, the reduction in expression of MHC
antigens and P2m in malignant breast tumours has been
already described by other authors (Fleming et al., 1981;
Natali et al., 1981, 1983, 1984; Bhan & DesMarais, 1983;
Rowe & Beverley, 1984; Sawtell et al., 1984; Sidky & Walker,
1984; Whitwell et al., 1984; Gottlinger et al., 1985; Hurli-
mann & Saraga, 1985; Perez et al., 1986; Zuk & Walker,
1987), however the positivity rates of the carcinomas in these
studies vary considerably. The different MoAbs and methods
applied, other criteria for interpretation of staining results
and the heterogeneous patterns of antigen expression might
explain the divergent results.
The expression, or absence, of MHC antigens in breast
carcinomas did not apparently influence the overall, or
disease-free, survival. The structure of our cohort for age and
tumour features is comparable to that of the studies by Shek
& Godolphin (1988) and Alexieva-Figusch et al. (1988), who
described the prognostic relevance of the classic parameters
such as tumour size, axillary lymph node status, ER and PR
levels. This comparability weakens the possible explanation
of our results being merely an outcome of a selective collec-
tion of patients. In addition, our follow-up period is almost
identical to that ofAlexieva-Figusch et al., exact data are not
given by Shek & Godolphin. The reliability of our results is
further strengthened by the identification of the axillary
lymph node and hormone receptor status as independent
prognostic factors for overall and disease-free survival. These
parameters confirm the observations of the studies cited
above as well as those from other investigations (Nemoto et
al., 1980; Baak et al., 1985; Bryan et al., 1986; Fisher et al.,
1987; Russo et al., 1987; Todd et al., 1987; Chevallier et al.,
1988).
In colorectal, but not in breast, carcinomas Stein et al.
(1988) could not find any influence of MHC antigens on
survival. Interestingly, this group described an inverse cor-
relation between the expression of HLA-A,B,C antigens and
the degree of differentiation in these carcinomas (Momburg
et al., 1986). Poorly differentiated carcinomas are charac-
terised by a worse clinical prognosis (Morson & Dawson,
1979). Thus, it seems that a similar discrepancy may also
exist for breast carcinomas. The correlation between the
reduction in MHC class I antigen expression and poor
tumour differentiation, a bad prognostic feature by itself,
favours the assumption that loss of MHC class I antigen may
impair prognosis. However, this idea is not confirmed by
survival analysis.
Several other aspects have to be considered before a prog-
nostic relevance of MHC antigens in breast carcinomas can
be excluded. From our study the possibility cannot be ruled
out that immunological mechanisms may be important in the
regulation of tumour growth of carcinoma subgroups, e.g.,
carcinomas of small size. Vanky et al. (1983b) and Klein
(1988) reported that, in an in vitro assay, tumour cells from
patients without metastases were lysed by autologous
peripheral blood lymphocytes but not by cells of patients
with metastases, and this antitumour reactivity correlated
with the survival of the tumour patients (Vafnky et al.,
1983a,b). In melanoma, Brocker et al. (1985) observed
shorter disease-free intervals in the case ofpatients with stage
I tumours positive for HLA-DR, while Fossati et al. (1986)
could not detect a correlation between the presence of HLA-
DR and survival in stage II disease. In vitro tests seem to
indicate that MHC class I antigen expression on tumour cells
is more relevant for putative in vivo tumour cytotoxicity by
T-cells than class II antigens. The differential expression of
MHC class I antigens has recently been described in colorec-
tal carcinomas (Rees et al., 1988; Smith et al., 1988; Lopez-
Nevot et al., 1989; Momburg et al., 1989), gastric and
laryngeal carcinomas (Lopez-Nevot et al., 1989) and breast
carcinomas (Muller & Stutte, 1988). An impact of MHC
class I subtypes on the clinical course of human breast
carcinomas is suggested by the latter group, who demon-
strated that HLA-A2 expression in breast carcinomas is con-
versely related to the number of axillary lymph node metas-
tases. When the same tumours were stained with a MoAb
specific for HLA-A,B such a correlation was not found.
From these results it was concluded that HLA-B expression
reduced the immunogenicity of breast carcinomas which
resulted in a higher frequency of metastases. Similar results
concerning the MHC class I antigens were reported by Eisen-
bach et al. (1983, 1984, 1985) based on a mouse tumour
model: the imbalance of H-2K/H-2D in favour of H-2D
enhanced the metastatic capacity of the tumour cells.
In appraising the relevance of MHC class II expression on
tumour cells, it is interesting to note that these antigens have
also been correlated with suppressive effects (Parmiani et al.,
1985). Although there is little information on the genetics of
suppression in man, suppressive phenomena seem to be
associated with HLA-DQ (Oliveira & Mitchinson, 1989). For
6 breast carcinomas the differential expression of MHC class
II antigens has been described by Natali et al. (1986). In
patients with metastatic melanoma the same authors
observed a more favourable prognosis when the metastases
expressed HLA-DQ, which does not fit with the association
of HLA-DQ and a supposed suppression of immune re-
sponse as mentioned above.
The experimental results providing strong evidence for the
importance of MHC antigen expression on tumour cells for
an effective antitumour immune defence against tumour cell
growth are not confirmed by our analysis of tumour patients
survival data. However, for breast carcinoma patients'
surveillance, our follow-up period is relatively short, since
recurrences may appear even after 20 years. In addition, the
percentage of data for the Kaplan-Meier estimates was rather
high (around 70%). The identification of nodal and hormone
receptor status as prognostic parameters in our cohort and
the comparison of our median follow-up period with other
studies proved that this interval was, nevertheless, long
enough for reliable interpretations. However, the study of
larger numbers of carcinoma patients and a longer follow-up
period are necessary to draw definitive conclusions.
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